

Fred R Hirsch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5690856/publications.pdf>

Version: 2024-02-01

156
papers

17,459
citations

38660

50
h-index

15218

126
g-index

158
all docs

158
docs citations

158
times ranked

18979
citing authors

#	ARTICLE	IF	CITATIONS
1	Lung cancer: current therapies and new targeted treatments. <i>Lancet, The</i> , 2017, 389, 299-311.	6.3	2,267
2	Epidermal Growth Factor Receptor in Non-Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis. <i>Journal of Clinical Oncology</i> , 2003, 21, 3798-3807.	0.8	1,333
3	PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. <i>Journal of Thoracic Oncology</i> , 2017, 12, 208-222.	0.5	1,067
4	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 853-861.e4.	7.7	725
5	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, 1051.	3.4	658
6	PD-L1 as a biomarker of response to immune-checkpoint inhibitors. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 345-362.	12.5	646
7	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1302-1311.	0.5	589
8	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 321-346.	1.2	586
9	Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6838-6845.	0.8	574
10	Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1248-1268.	0.5	515
11	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2015, 16, 763-774.	5.1	431
12	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 323-358.	0.5	408
13	New and emerging targeted treatments in advanced non-small-cell lung cancer. <i>Lancet, The</i> , 2016, 388, 1012-1024.	6.3	381
14	PD-L1 Expression in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 964-975.	0.5	329
15	Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non-Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 3351-3357.	0.8	278
16	Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?. <i>Journal of Thoracic Oncology</i> , 2015, 10, 985-989.	0.5	241
17	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 129-159.	1.2	241
18	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 630-643.	1.6	217

#	ARTICLE	IF	CITATIONS
19	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 377-407.	0.5	212
20	Lung Master Protocol (Lung-MAP)â€”A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. Clinical Cancer Research, 2015, 21, 1514-1524.	3.2	205
21	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	0.5	203
22	LAG-3 Protein Expression in Nonâ€”Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 2017, 12, 814-823.	0.5	192
23	Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer, 2003, 41, 29-42.	0.9	189
24	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)., 2018, 6, 75.		188
25	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	0.5	182
26	TIM-3, a promising target for cancer immunotherapy. OncoTargets and Therapy, 2018, Volume 11, 7005-7009.	1.0	172
27	Lymphocyteâ€”activation geneâ€”3, an important immune checkpoint in cancer. Cancer Science, 2016, 107, 1193-1197.	1.7	168
28	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	0.5	156
29	Fluorescence In Situ Hybridization, Immunohistochemistry, and Next-Generation Sequencing for Detection of EML4-ALK Rearrangement in Lung Cancer. Oncologist, 2015, 20, 316-322.	1.9	151
30	Long non-coding RNA <i>UCA1</i> induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in <i>EGFR</i> -mutant non-small cell lung cancer. Oncotarget, 2015, 6, 23582-23593.	0.8	144
31	FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies. Clinical Cancer Research, 2014, 20, 3299-3309.	3.2	141
32	â€”Interchangeabilityâ€”of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Modern Pathology, 2020, 33, 4-17.	2.9	135
33	Intratumoral Heterogeneity of <i>ALK</i> -Rearranged and <i>ALK</i> / <i>EGFR</i> Coaltered Lung Adenocarcinoma. Journal of Clinical Oncology, 2015, 33, 3701-3709.	0.8	129
34	Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncology, The, 2015, 16, 328-337.	5.1	124
35	Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?. Archives of Pathology and Laboratory Medicine, 2016, 140, 326-331.	1.2	118
36	Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. Journal of Thoracic Oncology, 2013, 8, 373-384.	0.5	113

#	ARTICLE	IF	CITATIONS
37	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 110-120.	0.5	108
38	EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. <i>Journal of Thoracic Oncology</i> , 2020, 15, 29-49.	0.5	106
39	HER2/neu expression in malignant lung tumors. <i>Seminars in Oncology</i> , 2002, 29, 51-58.	0.8	92
40	A Dramatic Response to Crizotinib in a Non-small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK. <i>Journal of Thoracic Oncology</i> , 2012, 7, e36-e38.	0.5	87
41	Review of Recent Advances in Fluorescence Bronchoscopy in Early Localization of Central Airway Lung Cancer. <i>Oncologist</i> , 2001, 6, 257-262.	1.9	83
42	MHC class II expression in lung cancer. <i>Lung Cancer</i> , 2017, 112, 75-80.	0.9	80
43	FGFR1 Expression Levels Predict BCG398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. <i>Clinical Cancer Research</i> , 2015, 21, 4356-4364.	3.2	75
44	Phase II Selection Design Trial of Concurrent Chemotherapy and Cetuximab Versus Chemotherapy Followed by Cetuximab in Advanced-Stage Non-small-Cell Lung Cancer: Southwest Oncology Group Study S0342. <i>Journal of Clinical Oncology</i> , 2010, 28, 4747-4754.	0.8	66
45	Biological Markers for Non-small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2006, 12, 3652-3656.	3.2	62
46	Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 101-114.	5.1	62
47	Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 2005, 17, 118-122.	1.1	60
48	The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1172-1183.	0.5	60
49	MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type. <i>Oncotarget</i> , 2014, 5, 7902-7916.	0.8	57
50	The role of HER2/neu expression and trastuzumab in non-small cell lung cancer. <i>Seminars in Oncology</i> , 2004, 31, 75-82.	0.8	56
51	ROS1 Immunohistochemistry Among Major Genotypes of Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 106-111.	1.1	54
52	Early detection of lung cancer by using an autoantibody panel in Chinese population. <i>Oncolmmunology</i> , 2018, 7, e1384108.	2.1	54
53	Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. <i>Clinical Lung Cancer</i> , 2018, 19, e421-e430.	1.1	53
54	cMET Exon 14 Skipping: From the Structure to the Clinic. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1423-1432.	0.5	51

#	ARTICLE	IF	CITATIONS
55	Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1388-1397.	0.5	49
56	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. <i>Medical Science Monitor</i> , 2017, 23, 1208-1216.	0.5	49
57	Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution. <i>Molecular Oncology</i> , 2020, 14, 1947-1965.	2.1	48
58	Design of a Phase III Clinical Trial with Prospective Biomarker Validation: SWOG S0819. <i>Clinical Cancer Research</i> , 2012, 18, 4004-4012.	3.2	45
59	From Mice to Men and Back: An Assessment of Preclinical Model Systems for the Study of Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2016, 11, 287-299.	0.5	45
60	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. <i>JCI Insight</i> , 2017, 2, e90449.	2.3	45
61	CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2257-2265.	1.9	41
62	A Phase II Study of Telisotuzumab Vedotin in Patients With MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). <i>Clinical Lung Cancer</i> , 2021, 22, 170-177.	1.1	41
63	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	0.5	40
64	KRAS G12C Mutant Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 507-520.	1.2	40
65	Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	39
66	OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers. <i>Translational Lung Cancer Research</i> , 2019, 8, 352-366.	1.3	38
67	EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. <i>Cancer Treatment Reviews</i> , 2019, 72, 15-27.	3.4	37
68	Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 96-104.	0.7	34
69	Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 205-217.	0.5	33
70	Galectin-9 in non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 136, 80-85.	0.9	32
71	Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 43-49.	1.1	31
72	EGFR TKIs plus local therapy demonstrated survival benefit than EGFR TKIs alone in EGFR mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases. <i>International Journal of Cancer</i> , 2019, 144, 2605-2612.	2.3	30

#	ARTICLE	IF	CITATIONS
73	The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. <i>Lung Cancer</i> , 2018, 125, 115-120.	0.9	29
74	T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 895-906.	1.3	29
75	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. <i>Lung Cancer</i> , 2017, 109, 1-8.	0.9	27
76	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 779-786.	1.1	27
77	Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation. <i>Journal of Thoracic Oncology</i> , 2022, 17, 214-227.	0.5	26
78	Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. <i>Journal of Pathology</i> , 2022, 257, 674-686.	2.1	26
79	Independent validation test of the vote-counting strategy used to rank biomarkers from published studies. <i>Biomarkers in Medicine</i> , 2015, 9, 751-761.	0.6	25
80	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. <i>Theranostics</i> , 2017, 7, 4753-4762.	4.6	25
81	sLAG-3 in non-small-cell lung cancer patients's serum. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4781-4784.	1.0	25
82	Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. <i>Journal of Thoracic Oncology</i> , 2017, 12, 27-35.	0.5	24
83	Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 72.	2.2	24
84	Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial. <i>Lung Cancer</i> , 2015, 88, 223-230.	0.9	23
85	Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Non-Small-Cell Lung Cancer: SWOG S0536. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1519-1528.	0.5	22
86	Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1496-1507.	0.5	22
87	c-MET as a biomarker in patients with surgically resected non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 133, 69-74.	0.9	22
88	Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). <i>Cancer</i> , 2015, 121, 2253-2261.	2.0	21
89	Clinical potential of necitumumab in non-small cell lung carcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5427-5437.	1.0	21
90	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). <i>Journal of Thoracic Oncology</i> , 2020, 15, 1748-1757.	0.5	21

#	ARTICLE	IF	CITATIONS
91	Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer. <i>Biology</i> , 2021, 10, 502.	1.3	21
92	Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1015-1020.	0.5	20
93	Genomic Testing in Lung Cancer: Past, Present, and Future. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 323-334.	2.3	20
94	Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions. <i>Clinical Lung Cancer</i> , 2019, 20, e517-e530.	1.1	19
95	“Companion Diagnostics” Has Their Time Come and Gone?. <i>Clinical Cancer Research</i> , 2014, 20, 4422-4424.	3.2	18
96	Serum microRNAs improving the diagnostic accuracy in lung cancer presenting with pulmonary nodules. <i>Journal of Thoracic Disease</i> , 2018, 10, 5080-5085.	0.6	18
97	Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. <i>Clinical Lung Cancer</i> , 2021, 22, 187-194.e1.	1.1	18
98	Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403). <i>Clinical Cancer Research</i> , 2022, 28, 3752-3760.	3.2	18
99	Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. <i>Oncologist</i> , 2021, 26, e1226-e1239.	1.9	17
100	Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma. <i>Medical Science Monitor</i> , 2016, 22, 276-283.	0.5	17
101	PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1364-1369.	0.5	16
102	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
103	Seven-microRNA panel for lung adenocarcinoma early diagnosis in patients presenting with ground-glass nodules. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5915-5926.	1.0	15
104	Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee “ International Association for the Study of Lung Cancer “ Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1718-1731.	0.5	15
105	Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma. <i>Oncologist</i> , 2022, 27, 476-486.	1.9	15
106	EGFR Gene Copy Number by FISH May Predict Outcome of Nectinmab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study. <i>Journal of Thoracic Oncology</i> , 2018, 13, 228-236.	0.5	14
107	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	13
108	Comparative expression analysis in small cell lung carcinoma reveals neuroendocrine pattern change in primary tumor versus lymph node metastases. <i>Translational Lung Cancer Research</i> , 2019, 8, 938-950.	1.3	13

#	ARTICLE	IF	CITATIONS
109	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 686-696.	0.5	13
110	Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. <i>PLoS ONE</i> , 2017, 12, e0172209.	1.1	13
111	Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1711-1717.	0.5	12
112	Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy. <i>Journal of Clinical Neuroscience</i> , 2016, 26, 46-49.	0.8	12
113	Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer. <i>Respiratory Research</i> , 2019, 20, 248.	1.4	12
114	The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 1029-1038.	1.3	12
115	Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial. <i>Clinical Lung Cancer</i> , 2022, 23, 21-33.	1.1	12
116	Biomarker Testing for Personalized Therapy in Lung Cancer in Low- and Middle-Income Countries. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 403-408.	1.8	11
117	EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism. <i>Lung Cancer</i> , 2018, 120, 82-87.	0.9	11
118	Preselection of Lung Cancer Cases Using FGFR1 mRNA and Gene Copy Number for Treatment With Ponatinib. <i>Clinical Lung Cancer</i> , 2019, 20, e39-e51.	1.1	11
119	Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse. <i>Translational Lung Cancer Research</i> , 2021, 10, 2452-2474.	1.3	11
120	Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer. <i>Cancer Cell</i> , 2022, 40, 575-577.	7.7	11
121	First-Generation Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer: Clinical Impact of the Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Assay. <i>Journal of Thoracic Oncology</i> , 2008, 3, S138-S142.	0.5	10
122	Expression of target molecules in lung cancer: Challenge for a new treatment paradigm. <i>Seminars in Oncology</i> , 2002, 29, 2-8.	0.8	9
123	Assessing the association of diabetes with lung cancer risk. <i>Translational Lung Cancer Research</i> , 2021, 10, 4200-4208.	1.3	9
124	Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1704-1717.	0.5	8
125	The International Association for the Study of Lung Cancer Molecular Database Project: Objectives, Challenges, and Opportunities. <i>Journal of Thoracic Oncology</i> , 2021, 16, 897-901.	0.5	8
126	Loss of STING expression is prognostic in non-small cell lung cancer. <i>Journal of Surgical Oncology</i> , 2022, 125, 1042-1052.	0.8	8

#	ARTICLE	IF	CITATIONS
127	Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-Cell Lung Cancer: SWOG S0635 and S0636 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, 84-92.	1.1	7
128	Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer. <i>Journal of Cancer</i> , 2020, 11, 551-558.	1.2	7
129	Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis. <i>Lung Cancer</i> , 2021, 156, 59-67.	0.9	7
130	Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab. <i>Journal of Clinical Oncology</i> , 2020, 38, 9532-9532.	0.8	7
131	Future developments in the treatment of lung cancer. <i>Lung Cancer</i> , 2002, 38, 81-85.	0.9	6
132	Heterogeneity in Tumors and Resistance to EGFR TKI Therapy Letter. <i>Cancer Research</i> , 2016, 76, 3109-3110.	0.4	6
133	Frequency and significance of epidermal growth factor receptor mutations detected by PCR methods in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 5125-5131.	0.8	6
134	Treatment of spine metastases in cancer: a review. <i>Journal of International Medical Research</i> , 2020, 48, 030006051988810.	0.4	6
135	Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives. <i>Lung Cancer</i> , 2021, 152, 157-164.	0.9	6
136	Adjuvant TKIs in NSCLC: what can we learn from RADIANT?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 689-690.	12.5	5
137	Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 640-650.e2.	1.1	5
138	Does selected immunological panel possess the value of predicting the prognosis of early-stage resectable non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2019, 8, 559-574.	1.3	5
139	EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC. <i>Clinical Lung Cancer</i> , 2022, 23, 60-71.	1.1	5
140	CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer. <i>Lung Cancer</i> , 2021, 162, 194-202.	0.9	5
141	Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
142	A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. <i>Clinical Lung Cancer</i> , 2018, 19, 450-456.	1.1	4
143	The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients. <i>Clinical Lung Cancer</i> , 2021, . .	1.1	4
144	International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2022, . .	0.5	4

#	ARTICLE	IF	CITATIONS
145	Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases. <i>OncoTargets and Therapy</i> , 2016, 9, 2409.	1.0	3
146	Physician Bias in Prophylactic Cranial Irradiation Decision Making—An Opportunity for a Patient Decision Aid. <i>Clinical Lung Cancer</i> , 2018, 19, 476-483.	1.1	3
147	PACIFIC trial: new perspectives for immunotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2018, 7, S19-S24.	1.3	2
148	A phase 1b/2 trial of dupilumab given in conjunction with PD-(L)1 blockade in the treatment of relapsed/refractory metastatic NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9139-TPS9139.	0.8	2
149	Longitudinal COVID-19 Vaccination—Induced Antibody Responses and Omicron Neutralization in Patients With Lung Cancer. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	2
150	Risk factors for nicotine dependence in Chinese patients with lung cancer. <i>Journal of International Medical Research</i> , 2019, 47, 391-397.	0.4	1
151	Programmed Cell Death Ligand 1 Expression in Resected Non—Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 22, e555-e562.	1.1	1
152	Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9576-9576.	0.8	1
153	EGFR expression and the flexibility of FLEX. <i>Lancet Oncology</i> , The, 2012, 13, 3-5.	5.1	0
154	Abstract S01-02: Assessing vulnerability of patients with lung cancer to SARS-CoV-2 infection based on serological antibody analyses. , 2021, , .		0
155	SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9623-9623.	0.8	0
156	Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100269.	0.6	0